The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; MSD; Pierre Fabre
Consulting or Advisory Role - Delcath Systems; Immunocore; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); MSD (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Consulting or Advisory Role - Health Advances
Research Funding - Immunocore (Inst)
 
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Immunocore; Incyte; Ipsen; Merck; MSD; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - Immunocore (Inst); Novartis (Inst)
 
Consulting or Advisory Role - Castle Biosciences; Immunocore
Research Funding - Immunocore (Inst); Verastem (Inst)
 
Consulting or Advisory Role - Castle Biosciences; Genzyme; Immunocore; InxMed; Iovance Biotherapeutics; Merck; OncoSec; Pierre Fabre; PureTech; Regeneron; Sorrento Therapeutics; TriSalus Life Sciences
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
 
Richard D. Carvajal
No Relationships to Disclose
 
Takami Sato
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; Iovance Biotherapeutics; LaRoche Posay; Merck; Novartis; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Joseph J. Sacco
No Relationships to Disclose
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - Bristol-Myers Squibb; Immunocore; Polaris; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Bristol Myers Squibb Foundation; MSD; Novartis; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst)
 
Alexandra Ikeguchi
No Relationships to Disclose
 
Leonel Fernando Hernandez-Aya
Consulting or Advisory Role - Bristol-Myers Squibb; Massive Bio
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); Polynoma (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi/Regeneron
 
Matthew Rioth
No Relationships to Disclose
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; BeiGene; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alphamab; Array BioPharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Compugen; CStone Pharmaceuticals; Eisai; EMD Serono; Incyte; Janssen; Merck; Mersana; Nektar; Novartis; Partner Therapeutics; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; Spring Bank; Synlogic; Tempest Therapeutics; Tesaro; TTC Oncology; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios; Array BioPharma; Astellas Pharma; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Corvus Pharmaceuticals (Inst); EMD Serono; Immatics; Incyte (Inst); Kadmon; Macrogenics (Inst); Merck (Inst); Moderna Therapeutics; Nektar; Spring bank; Trishula Therapeutics; Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Janssen; Merck; Novartis; Oncosec
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Serge Leyvraz
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Bayer
 
Enrique Espinosa
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - MSD Oncology
Research Funding - Roche (I)
Travel, Accommodations, Expenses - MSD Oncology
 
Laura Collins
Employment - Immunocore
 
Michelle L. McCully
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Sarah Lockwood
Consulting or Advisory Role - Immunocore
 
Shaad Essa Abdullah
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
Patents, Royalties, Other Intellectual Property - AU2019270277A1 - Treatment of Cancer; WO2020225552A1 - Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
 
Paul Nathan
No Relationships to Disclose